Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 3/20 | 0.50 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL629952 | 0.88 | MAOB (0.74) | MAOBLMNAHPGDAPPMAOA | |
| SCHEMBL29717105 | 0.87 | MAOB (0.63) | MAOBLMNAHPGDAPPMEN1 | |
| SCHEMBL710202 | 0.87 | MAOB (0.63) | MAOBLMNAHPGDAPPMEN1 | |
| SCHEMBL8204798 | 0.86 | ALOX5 (0.52) | MAOBHPGDALOX5APPMEN1 | |
| Methyl 2,4-Dihydroxybenzoate SCHEMBL5199862 | 0.84 | MAOB (0.68) | MAOBLMNAHPGDAPPMAOA | |
| SCHEMBL6577142 | 0.82 | LMNA (0.52) | LMNAHPGDMEN1HSP90AA1KMT2A | |
| SCHEMBL9526325 | 0.82 | MAOB (0.55) | MAOBLMNAHPGDALOX5APP | |
| SCHEMBL9939319 | 0.82 | PTPN7 (0.56) | MAOBLMNAHPGDALOX5MEN1 | |
| SCHEMBL28576913 | 0.82 | TDP1 (0.54) | MAOBLMNAHPGDAPPMEN1 | |
| SCHEMBL8204838 | 0.82 | HDAC8 (0.53) | MAOBLMNAHPGDAPPNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208518-B2 | Substituted furochromene compounds of antiinflammatory action | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2007-04-24 | — | — | US | disclosed |
| CN-1839138-A | Substituted furochromene compounds with anti-inflammatory action | PLIVA ISTRAZIVACKI INST D O O (HR) | 2006-09-27 | — | — | CN | disclosed |
| US-20060148890-A1 | Substituted furochromene compounds of antiinflammatory action | PLIVA-LSTRAZIVACKI INSTITUT D.O.O. (HR) | 2006-07-06 | — | — | US | disclosed |
| EP-1648901-A1 | SUBSTITUTED FUROCHROMENE COMPOUNDS OF ANTIINFLAMMATORY ACTION | PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005010006-A1 | SUBSTITUTED FUROCHROMENE COMPOUNDS OF ANTIINFLAMMATORY ACTION | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-02-03 | — | — | WO | disclosed |
| US-6136969-A | PROTEIN KINASE INHIBITORS; 4-HYDROXYBENZOIC ACID 3-(4-(4-FLUOROBENZOYLOXY)-BENZOYLAMINO)-AZEPAN-4-YL ESTER | HOFFMANN-LA ROCHE INC. (US) | 2000-10-24 | — | — | US | disclosed |
| US-5907038-A | PROTEIN KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 1999-05-25 | — | — | US | disclosed |
| CN-1199396-A | Novel azepanes and their ring homologues for therapy and prophylaxis of protein kinase mediated diseases | HOFFMANN LA ROCHE (CH) | 1998-11-18 | — | — | CN | disclosed |
| EP-0836592-A1 | AZEPANES AND THEIR RING HOMOLOGUES FOR THERAPY AND PROPHYLAXIS OF PROTEIN KINASE MEDIATED DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-04-22 | — | — | EP | disclosed |
| WO-1997002249-A1 | NOVEL AZEPANES AND THEIR RING HOMOLOGUES FOR THERAPY AND PROPHYLAXIS OF PROTEIN KINASE MEDIATED DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148890-A1 | Substituted furochromene compounds of antiinflammatory action | LTC4S, CYP11B2, CYP11B1 | MAOB 533/4885LMNA 1560/4885HPGD 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.